Stroke is the third leading cause of death in adults. Although vascular disease is the prime contributor to its pathogenesis, dyslipidaemia is not unambiguously established as a risk factor for stroke in the same way that it is for coronary artery disease. Non-statin treatments of dyslipidaemia have not been shown clearly to help in preventing stroke. However, large clinical trials of treatment with statins over a number of years have demonstrated that these drugs decrease ischaemic stroke rates in persons at risk. Whether this reflects the efficacy of statins in lowering low density lipoprotein-cholesterol (LDL-c) concentrations alone or whether additional mechanisms may apply is not clear.
Wannamethee SG, Shaper AG, Ebrahim S.HDL cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke2000; 311:882-8.
2.
Shahar E., Chambless LE, Rosamond WD et al. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke2003 ;34:623-31.
3.
Prospective Studies Collaboration.Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet1995;346:1647-53.
4.
Atkins D., Psaty BM, Koepsell TD, Longstreth WT, Jr., Larson EBCholesterol reduction and the risk for stroke in men. A meta-analysis of randomised, controlled trialsAnn Intern Med1993;119:136-45.
5.
Iso H., Jacobs DR, Jr., Wentworth D., Neaton JD, Cohen JDSerum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med1989;320:904-10.
6.
Benfante R., Yano K., Hwang LJ, Curb JD, Kagan A., Ross W.Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke1994;25:814-20.
7.
Horenstein RB , Smith DE, Mosca L.Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke2002;33:1863-8.
8.
Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DOStroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989Stroke1996;27:373-80.
9.
Whisnant JPModeling of risk factors for ischemic stroke. The Willis Lecture. Stroke1997;28:1840-4.
10.
Sridharan R.Risk factors for ischemic stroke: a case control analysis. Neuroepidemiology1992;11:24-30.
11.
Sacco RL, Benson RT, Kargman DE et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA2001;285:2729-35.
12.
Bots ML, Elwood PC, Nikitin Y. et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health2002;56(suppl 1):i19-24.
13.
Davis B., Vogt T., Frost PH et al. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke1998;29:1333-40.
Tanne D., Yaari S., Goldbourt U.High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8,586 men from the Israeli Ischemic Heart Disease Study . Stroke1997;28:83-7.
16.
Simons LA, Simons J., Friedlander Y., McCallum J.Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis2001;159:201-08. 17. Wilt TJ, Rubins HB, Robins SJ et al. Carotid atherosclerosis in men with low levels of HDL cholesterolStroke1997;28:1919-25.
17.
Mannami T., Konishi M., Baba S., Nishi N., Terao A.Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. Stroke1997;28:518-25. 19. Tanne D., Koren-Morag N., Graff E., Goldbourt U.Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factorCirculation2001 ;104:2892-7.
18.
Simons LA, Simons J., Friedlander Y., McCallum J.Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis2001;159:201-08.
19.
Sacco RLNewer risk factors for stroke. Neurology2001 ;57:S31-4.
20.
MacLeod MJ, De Lange RP, Breen G., Meiklejohn D., Lemmon H., Clair DSLack of association between apolipoprotein E genoype and ischaemic stroke in a Scottish population. Eur J Clin Invest2001;31:570-3.
21.
Slooter AJC , Bots ML, Havekes LM et al. Apolipoprotein E and Carotid Artery Atherosclerosis: The Rotterdam Study. Stroke2001;32:1947-52
22.
Djousse L., Myers RH, Province MA et al. Influence of Apolipoprotein E, Smoking, and Alcohol Intake on Carotid Atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke2002;33:1357-61.
23.
Frick MH, Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987;317:1237-45.
24.
Bloomfield Rubins H., Davenport J., Babikian V. et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation2001;103:2828-33.
25.
Blauw GJ, Lagaay AM, Smelt AH, Westendorp RGStroke, statins, and cholesterol. A meta-analysis of randomised, placebo-controlled, doubleblind trials with HMG-CoA reductase inhibitors. Stroke1997;28:946-50.
26.
Sacks FM, Moye LA, Davis BR et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation1998; 97:1446-52.
27.
Schwartz GG , Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRAearly recurrent ischemic CL study: a randomized controlled trial. JAMA2001;285:1711-18.
28.
Corvol J., Bouzamondo A., Sirol M., Hulot J., Sanchez P., Lechat P.Differential effects of lipid-lowering therapies on stroke prevention. A meta-analysis of randomised trials. Arch Intern Med2003 ;163:669-76.
29.
Heart Protection Study Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7-22.
30.
Shepherd J. , Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet2002;360:1623-30.
31.
Sever PS, Dahlöf B., Poulter N. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361:1149-58.
32.
Byington RP , Jukema JW, Salonen JT et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation1995;92: 2419-25.
33.
Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation2002;106:1690-5.
34.
Pedersen TR , Kjekshus J., Pyorala K. et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol1998;81:333-5.
35.
Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators (see comments). N Engl J Med1996;335:1001-09.
36.
The Lipid Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med1998; 339:1349-57.
37.
Shepherd J. , Cobbe SM, Ford et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group . N Engl J Med1995;333:1301-07.
38.
Byington RP , Davis BR, Plehn JF et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001;103:387-92.
39.
Shipley MJ, Pocock SJ, Marmot HGDoes plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18year follow-up of the Whitehall Study. BMJ1991;303:89-92.
40.
Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGTotal cholesterol and risk of mortality in the oldest old. Lancet1997;350:1119-23.
41.
Shepherd J. , Blauw GJ, Murphy MB et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol1999;84:1192-7.
42.
Vaughan CJ, Murphy MB, Buckley BMStatins do more than just lower cholesterol (see comments) (published erratum appears in Lancet 1997; 349:214). Lancet1996 ;348:1079-82.
43.
Vaughan CJ, Delanty N.Neuroprotective properties of statins in cerebral ischemia and stroke . Stroke1999;30:1969-73.
44.
Delanty N., Vaughan CJVascular effects of statins in stroke. Stroke1997; 28:2315-20.
